series-c-plus
Stage
3
Investors
About
HDAX Therapeutics develops potent and selective small molecule inhibitors targeting HDAC6 using a proprietary two-site binding mechanism, aiming to treat neurological and cardiovascular diseases.
Explore HDAX Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.